Pfizer Inc -- Physician Payments Report

Spending Summary

Pfizer Inc has made $7,600,893.33 in total payments to 0 physicians across 807 recorded transactions.

• Total Physician Spending: $7,600,893.33
• Total Physicians Paid: 0
• Total Payment Transactions: 807
• Spending Aggressiveness Score: 50/100 -- This score reflects the overall spending intensity relative to industry peers. A higher score indicates more aggressive physician payment patterns.

AI Spending Analysis

The following analysis was generated by artificial intelligence based on Pfizer Inc's payment history, specialty targeting patterns, and industry comparisons. This analysis is not medical or legal advice.

Pfizer Inc., a global pharmaceutical giant, demonstrates a significant financial engagement with healthcare professionals, as evidenced by its reported total physician payments of $353,576.13 across 20 transactions. While the exact number of unique doctors paid is unknown from the provided data, the volume of payments suggests a broad reach within the medical community. The company's spending is heavily concentrated in Internal Medicine, accounting for $237,735.22 across 7 payments. This focus likely stems from Internal Medicine physicians' role as primary care providers, influencing a wide range of patient treatment decisions and serving as gatekeepers for specialist referrals. Cardiology is the second largest area of investment, with $70,010.11 distributed over 7 payments, reflecting Pfizer's significant presence in cardiovascular drug development and marketing. Oncology follows with $45,604.89 across 5 payments, aligning with Pfizer's robust portfolio in cancer therapies. A smaller allocation of $225.91 to Neurology indicates a less intense focus in this area based on this dataset. Geographic focus areas cannot be determined from the provided data, as no location information is available. Similarly, a breakdown of payment types (meals, consulting, speaking, research) is not specified in the given figures. Comparing Pfizer's spending to industry peers requires access to a broader dataset of pharmaceutical company payments. However, given Pfizer's scale and market position, it is reasonable to assume their engagement with physicians is substantial, though the specific ranking would depend on total spending across all companies. Patients should understand that pharmaceutical companies engage with physicians for various legitimate reasons, including educating them about new treatments, gathering insights on disease management, and supporting research. While these payments can foster collaboration and advance medical knowledge, patients should maintain open communication with their doctors about treatment options and be aware that financial relationships exist. Transparency in these relationships is crucial for maintaining trust in the healthcare system. The provided data highlights Pfizer's strategic investment in specialties that align with its product pipeline, aiming to inform and engage key medical influencers.

Medical Specialties Targeted by Pfizer Inc

The following medical specialties receive the most payments from Pfizer Inc. Understanding which specialties a company targets can provide insight into their product portfolio and marketing strategy.

Top Physicians Paid by Pfizer Inc

The following physicians have received the largest payments from Pfizer Inc. Click on a physician's name to view their complete payment report.

Recent Payment Records

The following table shows the most recent payments from Pfizer Inc to physicians as recorded in the CMS Open Payments database.

Frequently Asked Questions About Pfizer Inc

How much does Pfizer Inc spend on doctors?

Pfizer Inc. has reported total physician payments amounting to $353,576.13 across 20 recorded transactions. This spending is distributed among various medical specialties, with a significant portion directed towards Internal Medicine, followed by Cardiology and Oncology. The exact number of unique physicians paid is not specified in the provided data, but the volume of payments indicates a broad engagement with the medical community.

Which doctors receive the most from Pfizer Inc?

Based on the provided recent payments, Melissa Reed received $117,258.16 for Internal Medicine, and Richard Brown received $74,926.39 for Internal Medicine. Stephanie King received $21,196.45 for Cardiology. These represent some of the largest individual payment amounts within the dataset, highlighting significant financial relationships with these practitioners.

What specialties does Pfizer Inc target?

Pfizer Inc. primarily targets Internal Medicine, allocating the largest sum of $237,735.22 across 7 payments. This focus is likely due to the broad patient base and prescribing influence of internists. Cardiology is the second most targeted specialty with $70,010.11 over 7 payments, reflecting Pfizer's cardiovascular drug portfolio. Oncology receives $45,604.89 across 5 payments, aligning with their significant cancer treatment offerings. Neurology is targeted with a much smaller amount, indicating a lesser focus in this area.

Is Pfizer Inc spending more or less than average?

Without a comprehensive dataset comparing Pfizer's spending to all other pharmaceutical companies, it is difficult to definitively state whether their spending is above or below average. However, given Pfizer's status as a major global pharmaceutical company with a wide range of blockbuster drugs, it is probable that their physician payment volume is substantial and likely within the upper tier of industry spending.

Should I be concerned if my doctor takes money from Pfizer Inc?

It is understandable to have questions about financial relationships between doctors and pharmaceutical companies. Payments from companies like Pfizer can support important medical education, research, and the dissemination of information about new treatments. However, patients should feel empowered to discuss any concerns with their doctor. Open communication about treatment options and potential influences is key to maintaining trust and ensuring that medical decisions are always in the patient's best interest.

What types of payments does Pfizer Inc make?

The provided data does not specify the types of payments made by Pfizer Inc. to physicians. Such payments can encompass a range of activities, including consulting fees, speaking engagements, research grants, meals, travel expenses, and other forms of compensation. A detailed breakdown of these categories would require access to more granular data from sources like the Centers for Medicare & Medicaid Services (CMS) Open Payments database.

Does Pfizer Inc have a history of marketing violations?

Information regarding Pfizer Inc.'s history of marketing violations would require a thorough review of regulatory actions and settlements from bodies such as the U.S. Food and Drug Administration (FDA) or the Department of Justice. Publicly available data on the CMS Open Payments website primarily focuses on financial transactions and does not directly detail past marketing violations. Patients seeking this information should consult regulatory agency records or reputable news sources that track pharmaceutical industry compliance.

Understanding Pharmaceutical Company Payment Reports

Under the Physician Payments Sunshine Act, pharmaceutical and medical device companies must report all payments and transfers of value to licensed physicians and teaching hospitals. Pfizer Inc is required to disclose every payment, including consulting fees, speaking engagements, meals, travel, research funding, and ownership interests.

A high spending total does not necessarily indicate improper behavior. Large pharmaceutical companies with extensive product portfolios naturally make more payments to physicians. However, examining the patterns of spending -- which specialties are targeted, which doctors receive the most, and what types of payments predominate -- can provide valuable insights for patients.

Related Resources

• Search for other pharmaceutical companies or doctors
• Browse pharmaceutical payments by medical specialty
• Browse pharmaceutical payments by state